SEC Form D filing

Vivace Therapeutics, Inc.

Biotech · Series B · Regulation D 506(b) · CA · Filed March 12, 2025

Offering amount: $35.0M
Exemption: Reg D 506(b)
Issuer state: CA
Filing date: March 12, 2025
Signature date: March 12, 2025
CIK: 0001630575

Public filing directories

Browse directories that group public SEC Form D records by the same filing tags shown on this page. FormDFlow surfaces public-disclosure data from SEC EDGAR. Nothing here is investment advice.

Sector: Biotech Month: March 2025 Stage and month: Series B

Summary

Auto-generated

Vivace Therapeutics drug development; $35M indicates series-b biotech venture.

Generated automatically by a language model from the public SEC filing; may contain errors. Verify against the source document on EDGAR. FormDFlow surfaces public-disclosure data from SEC EDGAR. Nothing here is investment advice.

Source

View on SEC EDGAR →Get alerts for filings like this →

FormDFlow surfaces public-disclosure data from SEC EDGAR. Nothing here is investment advice.